Luis Efrén Santos-Martínez

  • Citations Per Year
Learn More
Inhaled iloprost is a drug from the group of prostacyclins used in the treatment of pulmonary arterial hypertension. Its efficacy and safety have allowed its use as monotherapy and combination therapy. This review describes the product characteristics, amenable to treatment groups, and updated clinical evidence of drug use.
Pulmonary arterial hypertension (PAH) includes a group of chronic lung vascular diseases frequently complicated by right ventricle (RV) dysfunction and failure (1, 2). Under physiological conditions, the RV interacts with a low-pressure, low-resistance pulmonary circulation (3). However, under pathological conditions such as PAH, the RV is—at least(More)
We previously showed that lysozyme (Lzm-S), derived from leukocytes, caused myocardial depression in canine sepsis by binding to the endocardial endothelium to release nitric oxide (NO). NO then diffuses to adjacent myocytes to activate the cGMP pathway. In a canine right ventricular trabecular (RVT) preparation, Lzm-S also decreased the inotropic response(More)
In septic shock, cardiovascular collapse is caused by the release of inflammatory mediators. We previously found that lysozyme (Lzm-S), released from leukocytes, contributed to the myocardial depression and arterial vasodilation that develop in canine models of septic shock. To cause vasodilation, Lzm-S generates hydrogen peroxide (H(2)O(2)) that activates(More)
La hipertensión arterial pulmonar (HAP) es una entidad rara y se compone de un grupo de enfermedades que se caracterizan por el incremento progresivo de la presión pulmonar que conduce a disfunción del ventrículo derecho (VD) y a la muerte. A diferencia del paciente adulto con HAP, en el niño la etiología es muy diferente1. Los tipos de HAP más frecuentes y(More)
Inhaled iloprost is one of the most recent drugs from prostanoids group's in the treatment of pulmonary arterial hypertension. His place in pulmonary hypertension seen in the perioperative cardiovascular surgery has not been defined. In this review we analyze pulmonary hypertension group's susceptibles of cardiac surgery and its importance, besides the(More)
Physicians should always remember that a negative result in a superiority trial never would prove that the therapies under research are equivalent; more often, there may be a risk of type 2 (false negative) error. Equivalence and not inferiority studies demand high standards to provide reliable results. Physicians should take into account above all that the(More)
OBJECTIVES We sought to analyze exercise-derived mean pulmonary artery pressure (mPAP)-cardiac index (CI) relationship to expand the concepts regarding its nature and to better identify pulmonary hemodynamic responders to acute oxygen breathing (AO2B-99.5%) and to hydralazine (H) in extrinsic allergic alveolitis (EAA) and chronic interstitial lung disease(More)
OBJECTIVES We analyze exercise-derived mean pulmonary artery pressure/cardiac index relationship to expand the concepts regarding its nature and to better identify "responders" in idiopathic pulmonary arterial hypertension patients. METHODS Mean pulmonary artery pressure/cardiac index relationship and extrapolated pressure to zero flow were obtained in 40(More)